{"id":"NCT02631070","sponsor":"Celgene","briefTitle":"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","officialTitle":"A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-09","primaryCompletion":"2019-06-18","completion":"2020-11-26","firstPosted":"2015-12-15","resultsPosted":"2020-05-22","lastUpdate":"2021-12-17"},"enrollment":229,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndromes"],"interventions":[{"type":"DRUG","name":"Luspatercept","otherNames":["ACE-536"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Experimental Arm - Luspatercept (ACE-536)","type":"EXPERIMENTAL"},{"label":"Control Arm: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.\n\nThis is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in participants with anemia due to the Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate MDS with ring sideroblasts who require red blood cell (RBC) transfusions.","primaryOutcome":{"measure":"Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24","timeFrame":"From Week 1 through Week 24 of study treatment","effectByArm":[{"arm":"Luspatercept","deltaMin":37.91,"sd":null},{"arm":"Placebo","deltaMin":13.16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":74,"countries":["United States","Belgium","Canada","France","Germany","Italy","Netherlands","Spain","Sweden","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["30504333","30617198","31914241","32089218","30602619","36635381"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":153},"commonTop":["Fatigue","Diarrhoea","Oedema peripheral","Asthenia","Cough"]}}